Nxstage Medical, Inc. (NXTM) Discloses SEC Form 4 Insider Selling : Joseph E ... - Money Flow Index Print

Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,500 shares on Aug 4, 2015. The Insider selling transaction was disclosed on Aug 6, 2015 to the Securities and Exchange Commission. The shares were sold at $15.00 per share for a total value of $37,500.00.

NxStage Medical, Inc. (NXTM) shares are expected to touch $21 in the short term. This short term price target has been shared by 4 analysts. However, the standard deviation of short term price estimate has been valued at 4.24. The target price could hit $24 on the higher end and $15 on the lower end. Shares of Nxstage Medical, Inc. rose by 5.99% in the last five trading days and 2.44% for the last 4 weeks. Nxstage Medical, Inc. has dropped 21.23% during the last 3-month period . Year-to-Date the stock performance stands at -18.07%. Currently the company Insiders own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -5.19% in the total insider ownership. Institutional Investors own 95.4% of Company shares. During last 3 month period, -0.93% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 2,000 shares at an average price of $13.86 in a transaction dated on July 22, 2015. The total value of the transaction was worth $27,720. Shares of NxStage Medical, Inc. (NXTM) ended Tuesday session in red amid volatile trading. The shares closed down 0.13 points or 0.88% at $14.69 with 678,523 shares getting traded. Post opening the session at $14.87, the shares hit an intraday low of $14.61 and an intraday high of $15.12 and the price vacillated in this range throughout the day. The company has a market cap of $929 million and the number of outstanding shares have been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.